Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. II. Dose-response effect and the therapeutic window - PubMed (original) (raw)
Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. II. Dose-response effect and the therapeutic window
K Yanaka et al. J Neurosurg. 1996 Dec.
Abstract
The administration of massive doses of heparin has been demonstrated to reduce reperfusion injury. The authors have found that heparin's antileukocyte adhesion property may play a more important role than its anticoagulant property in preventing ischemia and reperfusion injury. Although the administration of massive doses of heparin has been demonstrated to reduce brain injury after ischemia and reperfusion, the optimum dosage and timing for heparin administration remain unknown. The purpose of this study was to evaluate the dose-response effect and determine the time during which heparin must be administered to inhibit leukocyte accumulation, reduce infarct size, and improve neurological outcome in rats subjected to 1 hour of cerebral ischemia and 48 hours of reperfusion. Forty-nine animals were included in the study. The animals receiving commercial unfractionated heparin at a total dose of 2.67 to 4 mg/kg showed a significant inhibition of leukocyte accumulation, reduced infarct size, and lessened neurological dysfunction 48 hours after reperfusion (p < 0.05) when compared to untreated animals. The animals receiving unfractionated heparin within 3 hours after reperfusion also showed significantly better results than untreated animals. These data indicate that standard doses of heparin prevent reperfusion injury, and relatively late postischemic administration of heparin also is effective in brain protection. These findings may have therapeutic potential as an adjunct to thrombolytic therapy and possibly for other perfusion deficiencies with leukocyte-endothelial interaction. In view of these encouraging experimental findings, the clinical application of heparin administration after ischemia and reperfusion warrants serious consideration.
Similar articles
- Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. I. Protective mechanism.
Yanaka K, Spellman SR, McCarthy JB, Oegema TR Jr, Low WC, Camarata PJ. Yanaka K, et al. J Neurosurg. 1996 Dec;85(6):1102-7. doi: 10.3171/jns.1996.85.6.1102. J Neurosurg. 1996. PMID: 8929502 - Antagonism of leukocyte adherence by synthetic fibronectin peptide V in a rat model of transient focal cerebral ischemia.
Yanaka K, Camarata PJ, Spellman SR, McCarthy JB, Furcht LT, Low WC. Yanaka K, et al. Neurosurgery. 1997 Mar;40(3):557-63; discussion 563-4. doi: 10.1097/00006123-199703000-00026. Neurosurgery. 1997. PMID: 9055296 - Neuroprotection by the stable nitroxide Tempol during reperfusion in a rat model of transient focal ischemia.
Rak R, Chao DL, Pluta RM, Mitchell JB, Oldfield EH, Watson JC. Rak R, et al. J Neurosurg. 2000 Apr;92(4):646-51. doi: 10.3171/jns.2000.92.4.0646. J Neurosurg. 2000. PMID: 10761655 - Heparin and Heparin-Derivatives in Post-Subarachnoid Hemorrhage Brain Injury: A Multimodal Therapy for a Multimodal Disease.
Hayman EG, Patel AP, James RF, Simard JM. Hayman EG, et al. Molecules. 2017 May 2;22(5):724. doi: 10.3390/molecules22050724. Molecules. 2017. PMID: 28468328 Free PMC article. Review. - Cerebral ischemia-reperfusion injury and adhesion.
Winquist RJ, Kerr S. Winquist RJ, et al. Neurology. 1997 Nov;49(5 Suppl 4):S23-6. doi: 10.1212/wnl.49.5_suppl_4.s23. Neurology. 1997. PMID: 9371145 Review. No abstract available.
Cited by
- Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies.
Pan J, Konstas AA, Bateman B, Ortolano GA, Pile-Spellman J. Pan J, et al. Neuroradiology. 2007 Feb;49(2):93-102. doi: 10.1007/s00234-006-0183-z. Epub 2006 Dec 20. Neuroradiology. 2007. PMID: 17177065 Free PMC article. Review. - Unfractionated heparin after TBI reduces in vivo cerebrovascular inflammation, brain edema and accelerates cognitive recovery.
Nagata K, Kumasaka K, Browne KD, Li S, St-Pierre J, Cognetti J, Marks J, Johnson VE, Smith DH, Pascual JL. Nagata K, et al. J Trauma Acute Care Surg. 2016 Dec;81(6):1088-1094. doi: 10.1097/TA.0000000000001215. J Trauma Acute Care Surg. 2016. PMID: 27533909 Free PMC article. - Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'.
Kraft P, De Meyer SF, Kleinschnitz C. Kraft P, et al. J Cereb Blood Flow Metab. 2012 Oct;32(10):1831-40. doi: 10.1038/jcbfm.2012.108. Epub 2012 Jul 18. J Cereb Blood Flow Metab. 2012. PMID: 22805877 Free PMC article. Review. - Neuroprotective profile of enoxaparin, a low molecular weight heparin, in in vivo models of cerebral ischemia or traumatic brain injury in rats: a review.
Stutzmann JM, Mary V, Wahl F, Grosjean-Piot O, Uzan A, Pratt J. Stutzmann JM, et al. CNS Drug Rev. 2002 Spring;8(1):1-30. doi: 10.1111/j.1527-3458.2002.tb00213.x. CNS Drug Rev. 2002. PMID: 12070524 Free PMC article. Review. - Tissue Injury Protection: The Other Face of Anticoagulant Treatments in the Context of Ischemia and Reperfusion Injury with a Focus on Transplantation.
Carré J, Kerforne T, Hauet T, Macchi L. Carré J, et al. Int J Mol Sci. 2023 Dec 14;24(24):17491. doi: 10.3390/ijms242417491. Int J Mol Sci. 2023. PMID: 38139319 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical